According to Zacks, “Natera, Inc. offers genetic testing and diagnostics with proprietary bioinformatics and molecular technology. Natera, Inc. is headquartered in San Carlos, California. “
A number of other research analysts have also issued reports on NTRA. BidaskClub lowered shares of Virtu Financial from a sell rating to a strong sell rating in a report on Wednesday, June 12th. Canaccord Genuity reiterated an average rating on shares of Kellogg in a report on Tuesday, June 25th. Finally, Piper Jaffray Companies set a $40.00 price objective on shares of Tapestry and gave the company a buy rating in a report on Monday, June 10th. Three equities research analysts have rated the stock with a hold rating, five have issued a buy rating and one has issued a strong buy rating to the company. Natera has a consensus rating of Buy and a consensus target price of $30.14.
Natera (NASDAQ:NTRA) last issued its quarterly earnings data on Thursday, May 9th. The medical research company reported ($0.54) earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($0.59) by $0.05. The business had revenue of $66.82 million during the quarter, compared to analyst estimates of $66.40 million. Natera had a negative net margin of 49.33% and a negative return on equity of 699.31%. Sell-side analysts forecast that Natera will post -2.17 EPS for the current fiscal year.
In other Natera news, Chairman Matthew Rabinowitz sold 1,418 shares of the stock in a transaction that occurred on Monday, June 10th. The shares were sold at an average price of $24.79, for a total transaction of $35,152.22. Following the completion of the sale, the chairman now owns 1,286,612 shares of the company’s stock, valued at approximately $31,895,111.48. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through the SEC website. Also, insider Jonathan Sheena sold 1,033 shares of the stock in a transaction that occurred on Monday, June 10th. The shares were sold at an average price of $24.79, for a total transaction of $25,608.07. Following the sale, the insider now directly owns 240,061 shares of the company’s stock, valued at approximately $5,951,112.19. The disclosure for this sale can be found here. In the last quarter, insiders sold 5,771 shares of company stock valued at $140,742. 9.29% of the stock is owned by company insiders.
A number of large investors have recently added to or reduced their stakes in the business. Legal & General Group Plc increased its position in Natera by 14.5% during the 4th quarter. Legal & General Group Plc now owns 5,826 shares of the medical research company’s stock valued at $81,000 after purchasing an additional 736 shares during the period. JGP Global Gestao de Recursos Ltda. grew its position in shares of Natera by 10.5% during the 1st quarter. JGP Global Gestao de Recursos Ltda. now owns 13,518 shares of the medical research company’s stock worth $279,000 after buying an additional 1,280 shares during the period. Great West Life Assurance Co. Can grew its position in shares of Natera by 136.8% during the 4th quarter. Great West Life Assurance Co. Can now owns 5,920 shares of the medical research company’s stock worth $80,000 after buying an additional 3,420 shares during the period. Northern Trust Corp grew its position in shares of Natera by 1.1% during the 4th quarter. Northern Trust Corp now owns 430,391 shares of the medical research company’s stock worth $6,009,000 after buying an additional 4,706 shares during the period. Finally, NumerixS Investment Technologies Inc grew its position in shares of Natera by 86.5% during the 1st quarter. NumerixS Investment Technologies Inc now owns 13,616 shares of the medical research company’s stock worth $272,000 after buying an additional 6,316 shares during the period. 80.27% of the stock is owned by institutional investors and hedge funds.
Natera, Inc, a diagnostics company, provides preconception and prenatal genetic testing services. It primarily offers Panorama, a non-invasive prenatal test that screens for chromosomal abnormalities of a fetus with a blood draw from the mother; Vistara, a single-gene mutations screening test to identify single-gene disorder; Horizon carrier screening to determine carrier status for various genetic diseases that could be passed on to the carrier's children; and Spectrum pre-implantation genetic screening and Spectrum pre-implantation genetic diagnosis to analyze chromosomal anomalies or inherited genetic conditions during an in vitro fertilization cycle.
Featured Article: Differences Between Momentum Investing and Long Term Investing
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Natera Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Natera and related companies with MarketBeat.com's FREE daily email newsletter.